74 patents
Utility
Triaryl Compounds for Treatment of PD-L1 Diseases
9 Feb 23
Pingchen FAN, Christopher LANGE, Venkat Reddy MALI, Darren J. McMURTRIE, Viengkham MALATHONG, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Yibin ZENG, Penglie ZHANG
Filed: 14 Jan 22
Utility
Combination Therapy Using a Chemokine Receptor 2 (CCR2) Antagonist and a PD-1/PD-L1 Inhibitor
26 Jan 23
The present disclosure is drawn to the combination therapy of a Chemokine Receptor 2 (CCR2) antagonist and a PD-1 and/or PD-L1 inhibitor in the treatment of cancer.
James J. CAMPBELL, Zhenhua MIAO, Thomas J. SCHALL, Israel CHARO, Shijie LI, Christine Marie JANSON, Rajinder SINGH, Karen EBSWORTH
Filed: 15 Mar 22
Utility
PROCESSES AND INTERMEDIATES IN THE PREPARATION OF C5aR ANTAGONISTS
12 Jan 23
Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.
Pingchen FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Rebecca M. LUI, Jay POWERS, Sreenivas PUNNA, Hiroko TANAKA, Penglie ZHANG
Filed: 8 Feb 22
Utility
Method of Treating C3 Glomerulopathy
10 Nov 22
Methods of treating a human suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Petrus BEKKER
Filed: 14 Feb 22
Utility
Azetidinyl-acetamides As CXCR7 Inhibitors
3 Nov 22
Pingchen FAN, Christopher W. LANGE, Rebecca M. LUI, Darren J. McMURTRIE, Ryan J. SCAMP, Ju YANG, Yibin ZENG, Penglie ZHANG
Filed: 18 Apr 22
Utility
Method of Treating Liver Fibrosis
6 Oct 22
A method of treating liver fibrosis with CCR2 antagonists is provided.
Zhenhua MIAO, Israel Charo
Filed: 11 May 22
Utility
DOSING AND EFFECT OF C5a ANTAGONIST WITH ANCA-ASSOCIATED VASCULITIS
22 Sep 22
Jun DENG, Petrus BEKKER, Jan HILLSON
Filed: 4 Nov 21
Utility
Treatment of Focal Segmental Glomerulosclerosis with CCR2 Antagonists
22 Sep 22
Provided herein are methods of treating focal segmental glomerulosclerosis, said methods include administering to a subject in need thereof a therapeutically effective amount of a CCR2 antagonist.
Zhenhua MIAO, Thomas J. Schall, Rajinder Singh
Filed: 3 Jun 22
Utility
Methods of Treating Generalized Pustular Psoriasis with an Antagonist of CCR6 or CXCR2
8 Sep 22
James J. CAMPBELL, Karen EBSWORTH, Antoni KRASINSKI, Venkat Reddy MALI, Jeffrey McMAHON, Rajinder SINGH, Ju YANG, Chao YU, Penglie ZHANG
Filed: 16 Nov 21
Utility
Treatment of C3 Glomerulopathy Using a C5A Inhibitor
18 Aug 22
Methods of treating certain human patient populations suffering from or susceptible to C3 glomerulopathy comprising administering to the human an effective amount of a C5aR antagonist are provided.
Thomas J. SCHALL
Filed: 20 Dec 21
Utility
Methods of Treating Solid Tumors with CCR2 Antagonists
4 Aug 22
James J. CAMPBELL, Rajinder SINGH, Samuel HWANG, Xuesong WU
Filed: 22 Sep 21
Utility
Capsule Formulations
28 Jul 22
Manmohan Reddy LELETI, Jay P. POWERS
Filed: 8 Dec 21
Utility
Method of Treating Focal Segmental Glomerulosclerosis
21 Jul 22
A method of treating focal segmental glomerulosclerosis with a compound of Formula I is provided.
Zhenhua MIAO, Thomas SCHALL, Rajinder SINGH
Filed: 8 Apr 22
Utility
Substituted Anilines As CCR(4) Antagonists
23 Jun 22
Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
Trevor T. CHARVAT, Junfa FAN, Christopher W. LANGE, Manmohan Reddy LELETI, Yandong LI, Venkat Reddy MALI, Jeffrey P. McMAHON, Jay POWERS, Sreenivas PUNNA, Ju YANG
Filed: 9 Sep 21
Utility
Indane-amines As PD-L1 Antagonists
9 Jun 22
Christopher LANGE, Sreenivas PUNNA, Rajinder SINGH, Ju YANG, Penglie ZHANG
Filed: 30 Aug 21
Utility
Methods of Treating Hidradenitis Suppurativa
28 Apr 22
Shijie LI, Rajinder Singh, Thomas J. Schall, Peter Staehr
Filed: 27 Oct 21
Utility
CXCR7 Antagonists
28 Apr 22
Junfa FAN, Antoni KRASINSKI, Christopher W. LANGE, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
Filed: 27 May 21
Utility
Macrocyclic Immunomodulators
21 Apr 22
Viengkham MALATHONG, Jeffrey McMAHON, Darren J. McMURTRIE, Sreenivas PUNNA, Howard S. ROTH, Rajinder SINGH, Penglie ZHANG
Filed: 3 Jun 21
Utility
FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
31 Mar 22
Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
Filed: 4 May 21
Utility
Aza-aryl 1H-PYRAZOL-1-YL Benzene Sulfonamides
17 Feb 22
Compounds are provided that act as potent antagonists of the CCR(9) receptor.
Xi CHEN, Junfa FAN, Pingchen FAN, Antoni KRASINSKI, Lianfa LI, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
Filed: 29 Oct 21